Late‐Breaking Abstracts
Bibliographic record
Abstract
Background: Atherosclerosis is associated with heightened risk of venous thromboembolism (VTE) and patients with VTE are at increased risk of atherothrombosis.Shared pathobiologies likely underlying these associations include endothelial dysfunction, inflammation, and thrombin and platelet activation.Strategies targeting more than one of these pathways may have broad benefits for reducing thrombotic events across the spectrum of vascular territories in atherosclerosis.Aims: To examine first and total arterial and venous vascular events in patients with symptomatic peripheral artery disease (PAD) after lower extremity revascularization (LER) as well as the effect of lowdose anticoagulation added to low-dose antiplatelet therapy on these outcomes.Methods: VOYAGER PAD randomized 6,564 patients to rivaroxaban 2.5 mg twice daily or placebo on a background of aspirin 100 mg daily.Clopidogrel was allowed at the investigator's discretion.Patients requiring therapeutic anticoagulation were excluded.Adjudicated events included MI, ischemic stroke, acute limb ischemia, major vascular amputation, and VTE (deep vein thrombosis, pulmonary embolism).First and total events were analyzed by proportional hazards models with excluded deaths treated as competing terminal events.Results: Over 28 months (median), first and total event rates were 7.1 and 10.3 events/100 patient-years, respectively, in the placebo group.Rivaroxaban reduced first vascular event by 24% (HR 0.76, 95%CI 0.67-0.87,P < 0.0001) and total vascular events by 23% (HR 0.77, 95%CI 0.67-0.89,P = 0.0005) (Figure 1).Among 925 patients with a nonfatal first event, 31% percent had a second event, with arterial the predominant type in both treatment arms (268 arterial, 16 venous) (Figure 2).Conclusions: PAD patients are at high risk for arterial and venous vascular events after LER.VOYAGER PAD provides evidence for the benefit of dual pathway inhibition, combining low-dose anticoagulation with low-dose antiplatelet therapy, over antiplatelet therapy alone to protect against the adverse arterial and venous
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.004 | 0.017 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.003 | 0.003 |
| Science and technology studies | 0.002 | 0.001 |
| Scholarly communication | 0.008 | 0.002 |
| Open science | 0.002 | 0.003 |
| Research integrity | 0.003 | 0.003 |
| Insufficient payload (model declined to judge) | 0.719 | 0.475 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".